110 related articles for article (PubMed ID: 12366664)
1. The relevance of oncogenes as prognostic markers in cervical cancer.
Soh LT; Heng D; Lee IW; Ho TH; Hui KM
Int J Gynecol Cancer; 2002; 12(5):465-74. PubMed ID: 12366664
[TBL] [Abstract][Full Text] [Related]
2. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
3. Detection of human papillomavirus genome and analysis of expression of c-myc and Ha-ras oncogenes in invasive cervical carcinomas.
Iwasaka T; Yokoyama M; Oh-uchida M; Matsuo N; Hara K; Fukuyama K; Hachisuga T; Fukuda K; Sugimori H
Gynecol Oncol; 1992 Sep; 46(3):298-303. PubMed ID: 1326470
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection.
Zhang A; Månér S; Betz R; Angström T; Stendahl U; Bergman F; Zetterberg A; Wallin KL
Int J Cancer; 2002 Oct; 101(5):427-33. PubMed ID: 12216070
[TBL] [Abstract][Full Text] [Related]
5. Relationships between c-Ki-ras mutations, HPV types, and prognostic indicators in invasive endocervical adenocarcinomas.
Koulos JP; Wright TC; Mitchell MF; Silva E; Atkinson EN; Richart RM
Gynecol Oncol; 1993 Mar; 48(3):364-9. PubMed ID: 8385060
[TBL] [Abstract][Full Text] [Related]
6. [c-myc and c-Ha-ras proto-oncogenes in cervical cancer: prognostic value].
Riou G; Sheng ZM; Zhou D; Lusinchi A; Le Doussal V; Barrois M
Bull Cancer; 1990; 77(4):341-7. PubMed ID: 2191730
[TBL] [Abstract][Full Text] [Related]
7. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
8. Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions.
Mourón SA; Abba MC; Güerci A; Gómez MA; Dulout FN; Golijow CD
Mutat Res; 2000 Aug; 469(1):127-34. PubMed ID: 10946249
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic significance of Bmi-1 expression in human cervical cancer.
Min L; Dong-Xiang S; Xiao-Tong G; Ting G; Xiao-Dong C
Acta Obstet Gynecol Scand; 2011 Jul; 90(7):737-45. PubMed ID: 21309753
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas.
Ivanova TA; Golovina DA; Zavalishina LE; Volgareva GM; Katargin AN; Andreeva YY; Frank GA; Kisseljov FL; Kisseljova NP
BMC Cancer; 2007 Mar; 7():47. PubMed ID: 17359536
[TBL] [Abstract][Full Text] [Related]
11. Mutations and amplification of oncogenes in endometrial cancer.
Niederacher D; An HX; Cho YJ; Hantschmann P; Bender HG; Beckmann MW
Oncology; 1999; 56(1):59-65. PubMed ID: 9885379
[TBL] [Abstract][Full Text] [Related]
12. Analysis of ras point mutations and human papillomavirus 16 and 18 in cervical carcinomata and their metastases.
Willis G; Jennings B; Ball RY; New NE; Gibson I
Gynecol Oncol; 1993 Jun; 49(3):359-64. PubMed ID: 8390962
[TBL] [Abstract][Full Text] [Related]
13. K-RAS point mutation, and amplification of C-MYC and C-ERBB2 in colon adenocarcinoma.
Kruszewski W; Kowara R; Rzepko R; Warezak C; Zieliński J; Gryglewski G; Kopacz A; Jastrzebski T; Pawełczyk T
Folia Histochem Cytobiol; 2004; 42(3):173-9. PubMed ID: 15493579
[TBL] [Abstract][Full Text] [Related]
14. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
15. c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions.
Pelisson I; Soler C; Pechoux C; Chignol MC; Viac J; Euvrard S; Chardonnet Y
J Dermatol Sci; 1992 Jan; 3(1):56-67. PubMed ID: 1317208
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer.
Lagerholm S; Lagerholm S; Dutta S; Nair P
Scand J Gastroenterol; 2005 Nov; 40(11):1343-50. PubMed ID: 16334444
[TBL] [Abstract][Full Text] [Related]
17. HPV-16 E2 physical status and molecular evolution in vivo in cervical carcinomas.
Kahla S; Kochbati L; Chanoufi MB; Maalej M; Oueslati R
Int J Biol Markers; 2014 Mar; 29(1):e78-85. PubMed ID: 24170557
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix.
Kihana T; Tsuda H; Teshima S; Nomoto K; Tsugane S; Sonoda T; Matsuura S; Hirohashi S
Cancer; 1994 Jan; 73(1):148-53. PubMed ID: 7506116
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade.
Harvey WH; Harb OS; Kosak ST; Sheaffer JC; Lowe LR; Heerema NA
Leuk Res; 1994 Aug; 18(8):577-85. PubMed ID: 7520517
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the P16 gene in uterine cervical carcinoma from Indian patients.
Tripathi A; Banerjee S; Roy A; Roychowdhury S; Panda CK
Int J Gynecol Cancer; 2003; 13(4):472-9. PubMed ID: 12911724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
